Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrutiny Following Outlier Investigation Prompts Tenet Board Reorganization

This article was originally published in The Gray Sheet

Executive Summary

Tenet Healthcare's voluntary adoption of outlier policy changes sparked by recent CMS scrutiny brought about a 79% decrease in hospital outlier payments during the firm's most recent quarter

You may also be interested in...



CMS Guidance Delineates Specialty Hospital Moratorium Exclusion Criteria

The Centers for Medicare & Medicaid Services will use four criteria to determine whether to exclude specialty hospitals from an 18-month moratorium prohibiting physician self-referrals and investment

CMS Guidance Delineates Specialty Hospital Moratorium Exclusion Criteria

The Centers for Medicare & Medicaid Services will use four criteria to determine whether to exclude specialty hospitals from an 18-month moratorium prohibiting physician self-referrals and investment

Tenet’s legal woes accelerate

$54 mil. settlement is reached with the Justice Department and the U.S. Attorney for the Eastern District of California regarding allegations that two doctors performed unnecessary cardiac procedures at Redding Medical Center (1"The Gray Sheet" April 21, 2003, p. 17). Under the terms of the settlement, Tenet, its subsidiaries and Redding Medical Center deny that they deliberately submitted false claims to Medicare for the unnecessary procedures...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018254

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel